C-CAR168 for autoimmune diseases not helped by standard care
Part of Brain & nervous system, Cancer, Eyes & vision, Immune system & allergy, Skin clinical trials.
This trial tests a new treatment called C-CAR168 for people with certain autoimmune diseases that have not improved with standard therapies. It aims to see if this treatment can help control the disease.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are between 18 and 70 years old.
- You have been diagnosed with multiple sclerosis, neuromyelitis optica, myasthenia gravis, lupus, systemic sclerosis, or immune-mediated necrotizing myopathy for at least 6 months.
- Standard treatments have not worked well for you.
- Your bone marrow, blood clotting, heart, lungs, liver, and kidneys are working well enough.
- You do not have active infections like hepatitis B or C, HIV, or certain other viruses.
- You have not had a previous treatment with CAR-T cells or gene-modified T cells.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new cell therapy called C-CAR168 for people with autoimmune diseases affecting the brain and spinal cord, such as multiple sclerosis, neuromyelitis optica, autoimmune encephalitis, or stiff person spectrum disorder. It is for patients whose condition has not improved with standard treatments.
This trial tests a new CAR-T cell therapy (C-CAR168) for people with several autoimmune diseases that have not responded to standard treatments. It aims to see if this therapy can control the disease when other medicines have failed.
This trial tests a new kind of cell therapy (UCAR-T) that targets CD19 and BCMA proteins on immune cells. It is for people with certain neurological autoimmune diseases like multiple sclerosis, myasthenia gravis, chronic inflammatory demyelinating polyneuropathy, or autoimmune encephalitis who have not responded well to standard treatments.
This study tests a new cell therapy called CAR-T (using your own immune cells) for people with severe autoimmune diseases like lupus, scleroderma, or myositis that have not improved with standard treatments. The goal is to see if it can safely reduce disease activity.
This trial tests a new treatment using your own immune cells (called CAR-T cells) designed to target and attack cells that cause autoimmune diseases. It is for people with lupus, Sjögren's syndrome, inflammatory myopathy, scleroderma, Behcet's disease, ANCA-associated vasculitis, IgG4-related disease, antiphospholipid syndrome, or thrombotic thrombocytopenic purpura who have not improved with standard therapies.
This trial tests a fast-acting CAR-T therapy that targets BCMA and CD70 proteins to treat lupus. It may help people with moderate-to-severe lupus that hasn't improved with standard treatments.
Hear when a new Neuromyelitis Optica Spectrum Disorder trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.